Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Truist analyst Peter Osterland lowered the firm’s price target on Albemarle (ALB) to $85 from $96 and keeps a Hold rating on the shares after ...
Laufey Last week Weeks at no. 1 Weeks on chart Laufey/AWAL Greatest gainer this week Gains In Performance Week of February 15, 2025 click to see more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback